Tempest Therapeutics, Inc.

NasdaqCM:TPST Stock Report

Market Cap: US$40.3m

Tempest Therapeutics Management

Management criteria checks 3/4

Tempest Therapeutics' CEO is Steve Brady, appointed in Jun 2021, has a tenure of 4.42 years. total yearly compensation is $1.87M, comprised of 32% salary and 68% bonuses, including company stock and options. directly owns 0.081% of the company’s shares, worth $32.77K. The average tenure of the management team and the board of directors is 4.4 years and 4.4 years respectively.

Key information

Steve Brady

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage32.05%
CEO tenure4.4yrs
CEO ownership0.08%
Management average tenure4.4yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Tempest Therapeutics GAAP EPS of -$0.79

Aug 15

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

Jan 04

CEO Compensation Analysis

How has Steve Brady's remuneration changed compared to Tempest Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$36m

Jun 30 2025n/an/a

-US$43m

Mar 31 2025n/an/a

-US$45m

Dec 31 2024US$2mUS$600k

-US$42m

Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$32m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$7mUS$567k

-US$29m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$2mUS$530k

-US$36m

Sep 30 2022n/an/a

-US$34m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$715kUS$475k

-US$28m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$22m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$896kUS$461k

-US$19m

Compensation vs Market: Steve's total compensation ($USD1.87M) is above average for companies of similar size in the US market ($USD598.08K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Brady (55 yo)

4.4yrs
Tenure
US$1,872,299
Compensation

Mr. Stephen R. Brady, also known as Steve, LL M., J.D. served as an Independent Director at Atreca, Inc. since July 2021. He has been Chief Executive Officer & Director at Tempest Therapeutics Inc. since J...

Leadership Team

NamePositionTenureCompensationOwnership
Stephen Brady
CEO, President & Director4.4yrsUS$1.87m0.081%
$ 32.8k
Nicholas Maestas
CFO, Head of Corporate Strategy & Secretary4.3yrsUS$622.10k0.015%
$ 6.0k
Samuel Whiting
Executive VP5yrsUS$1.06m0.013%
$ 5.4k
Justin Trojanowski
Corporate Controller3.2yrsno data0.038%
$ 15.5k
4.4yrs
Average Tenure
50yo
Average Age

Experienced Management: TPST's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stephen Brady
CEO, President & Director4.4yrsUS$1.87m0.081%
$ 32.8k
Christine Pellizzari
Independent Director4.3yrsUS$95.40k0%
$ 0
Michael Raab
Independent Chairman4.4yrsUS$145.90k0%
$ 0
Geoffrey Nichol
Independent Director4.4yrsUS$95.90k0%
$ 0
Andrew Pardoll
Member of Advisory Boardno datano datano data
Raymond DuBois
Member of Advisory Boardno datano datano data
Petpiboon Prasit
Member of Advisory Boardno datano datano data
Benjamin Cravatt
Member of Advisory Board6.5yrsno datano data
Ronit Simantov
Independent Director4.3yrsUS$88.40k0%
$ 0
Jason J. Luke
Member of Advisory Boardno datano datano data
Toni Choueiri
Member of Advisory Boardno datano datano data
Russell Vance
Member of Advisory Board4.2yrsno datano data
4.4yrs
Average Tenure
60yo
Average Age

Experienced Board: TPST's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/16 03:24
End of Day Share Price 2025/11/14 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tempest Therapeutics, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Maurice RaycroftJefferies LLC
Aydin HuseynovLadenburg Thalmann & Company